Contact this trialFirst, we need to learn more about you.
PD-1/PD-L1 Checkpoint Inhibitor
Combination Immunotherapy for Cancer
Recruiting1 awardPhase 2
Buffalo, New York
This trial is studying a combination of immunotherapies to see if they help patients with cancer that has progressed after treatment with a PD-1/PD-L1 checkpoint inhibitor. The study has five cohorts of patients. All patients will receive N-803 once every 3 weeks. Patients in Cohorts 1-4 will receive the combination treatment of PD-1/PD-L1 checkpoint inhibitor plus N-803 for up to 17 cycles. Some patients who experience disease progression while on study in Cohorts 1-4 may roll over into Cohort 5 and receive combination therapy with a PD-1/PD-L1 checkpoint inhibitor, N
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.